Viking Therapeutics' Obesity Drug Market Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: stocktwits
- Clinical Trial Catalyst: Viking Therapeutics is set to release maintenance study data in Q3, which could provide crucial insights into the long-term use of its obesity drug VK2735, with positive results likely to enhance market competitiveness and attract more investor interest.
- Dual-Track Development Strategy: VK2735, a dual GLP-1/GIP receptor agonist, is advancing in both subcutaneous and oral formulations, and the growing market demand for such flexibility may allow Viking to stand out in competition against giants like Novo Nordisk and Eli Lilly.
- Sufficient Funding for Development: As of the end of Q1, Viking Therapeutics had a cash runway of $603 million, which is adequate to support all its R&D plans through 2027, ensuring ongoing investment and innovation in the obesity drug market.
- Optimistic Analyst Ratings: According to Koyfin, 18 out of 20 analysts covering VKTX rate it as 'Buy' or higher, with a 12-month average price target of $92.58, indicating a potential upside of about 166% from the last closing price, reflecting strong market confidence in its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.370
Low
70.00
Averages
97.00
High
125.00
Current: 32.370
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Phase 3 Study Progress
- Clinical Trial Progress: Viking Therapeutics' leading anti-obesity candidate VK2735 is currently in phase 3 studies, with data expected next year; if results are positive, the stock could significantly rise from its current price of $32.
- Market Outlook: Despite an 8% decline in stock price this year, Viking Therapeutics has the potential to carve out a niche in the rapidly growing anti-obesity market, especially with late-stage studies for its oral VK2735 formulation expected to start by year-end.
- Investment Risk Assessment: Although VK2735 showed strong results in phase 2 trials, the increasing competition in the anti-obesity sector means Viking Therapeutics must exceed market expectations in upcoming trials to ensure stock price appreciation.
- Investment Recommendation: For risk-tolerant investors, the current stock price may present an attractive entry point; however, conservative investors might want to explore other options due to potential volatility.
See More
Viking Therapeutics' Obesity Drug Market Outlook
- Clinical Trial Catalyst: Viking Therapeutics is set to release maintenance study data in Q3, which could provide crucial insights into the long-term use of its obesity drug VK2735, with positive results likely to enhance market competitiveness and attract more investor interest.
- Dual-Track Development Strategy: VK2735, a dual GLP-1/GIP receptor agonist, is advancing in both subcutaneous and oral formulations, and the growing market demand for such flexibility may allow Viking to stand out in competition against giants like Novo Nordisk and Eli Lilly.
- Sufficient Funding for Development: As of the end of Q1, Viking Therapeutics had a cash runway of $603 million, which is adequate to support all its R&D plans through 2027, ensuring ongoing investment and innovation in the obesity drug market.
- Optimistic Analyst Ratings: According to Koyfin, 18 out of 20 analysts covering VKTX rate it as 'Buy' or higher, with a 12-month average price target of $92.58, indicating a potential upside of about 166% from the last closing price, reflecting strong market confidence in its future performance.
See More
GLP-1 Drug Market Poised for Significant Growth
- Market Potential: Analysts at Grand View Research estimate that the global GLP-1 drug market will exceed $185 billion by 2033, with a compound annual growth rate of 12.4%, indicating significant growth potential that could transform the healthcare landscape.
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, generated $19.8 billion in revenue during Q1 2026, reflecting an impressive growth rate of 56%, showcasing the company's robust competitive position in the rapidly expanding GLP-1 market.
- Viking Therapeutics' Potential: Although Viking Therapeutics has no approved drugs yet, its GLP-1 drug VK2735 has shown promising results in clinical trials, and if approved, could significantly boost its market value and become an attractive acquisition target for larger healthcare firms.
- Investment Risks and Opportunities: While Eli Lilly's high valuation at a 39x P/E ratio may seem steep, its strong fundamentals make it a compelling long-term investment, whereas Viking Therapeutics presents a higher risk-reward profile, appealing to investors looking for diversification.
See More
Viking Therapeutics Faces Key Catalysts Ahead
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in phase 3 trials, with data expected next year; if it can replicate its strong phase 2 results, the stock could see significant appreciation, attracting more investor interest.
- Market Potential: With the anti-obesity drug market projected to grow rapidly over the next decade, Viking Therapeutics faces heightened market expectations, and despite an 8% decline in stock price this year, it is still viewed as a potential investment opportunity.
- Product Line Expansion: The company plans to initiate late-stage studies for an oral formulation of VK2735 by year-end, which could further strengthen its position in the competitive weight-loss drug market and enhance future revenue potential.
- Risks and Opportunities: While Viking Therapeutics' stock is seen as an attractive investment option, investors must be aware of potential risks, particularly setbacks in clinical trials, and it is advisable for risk-tolerant investors to consider initiating a small position.
See More
Anti-Obesity Drug Market Faces Potential Disruption
- Market Dominance: Eli Lilly and Novo Nordisk dominate the U.S. obesity and diabetes treatment market with their GLP-1 drugs, creating a potential duopoly that presents opportunities for new entrants to challenge the status quo.
- Viking Therapeutics' Competitiveness: Viking Therapeutics' VK2735 shows promising early data in phase 2 trials, with participants losing up to 14.7% of their weight over 13 weeks, indicating its competitive edge in a market with limited share.
- Market Potential: If the anti-obesity drug market reaches $100 billion in the next decade, Viking only needs to capture 1% of the market to significantly boost its valuation, highlighting its potential threat to the revenues of Lilly and Novo Nordisk.
- Clinical Trial Progress: VK2735's phase 3 trials have just completed enrollment, with results expected by 2027; if these results confirm earlier data, it will greatly enhance its competitive position in the obesity drug market.
See More
Viking Therapeutics Aims to Disrupt Obesity Drug Market
- Competitive Candidate: Viking Therapeutics' VK2735 demonstrated strong early data in two phase 2 trials, with participants losing 14.7% and 12.2% of their weight over 13 weeks, indicating its potential to compete with Eli Lilly and Novo Nordisk in the obesity drug market.
- Market Share Opportunity: With a market cap of just $3.5 billion, capturing even 1% of the projected $100 billion weight-loss drug market could significantly elevate Viking's valuation, providing substantial returns for shareholders.
- Clinical Trial Progress: The phase 3 trials for the injectable formulation of VK2735 completed enrollment earlier this year, with top-line data not expected until 2027, while the oral formulation's phase 3 trial is anticipated to begin by the end of this year.
- Industry Competitive Landscape: Although VK2735 shows competitive potential in the short term, it must prove its long-term efficacy against late-stage candidates like Eli Lilly's retatrutide and Novo Nordisk's CagriSema to secure a foothold in the market.
See More
Viking Therapeutics Phase 3 Study Progress
- Clinical Trial Progress: Viking Therapeutics' leading anti-obesity candidate VK2735 is currently in phase 3 studies, with data expected next year; if results are positive, the stock could significantly rise from its current price of $32.
- Market Outlook: Despite an 8% decline in stock price this year, Viking Therapeutics has the potential to carve out a niche in the rapidly growing anti-obesity market, especially with late-stage studies for its oral VK2735 formulation expected to start by year-end.
- Investment Risk Assessment: Although VK2735 showed strong results in phase 2 trials, the increasing competition in the anti-obesity sector means Viking Therapeutics must exceed market expectations in upcoming trials to ensure stock price appreciation.
- Investment Recommendation: For risk-tolerant investors, the current stock price may present an attractive entry point; however, conservative investors might want to explore other options due to potential volatility.
See More
Viking Therapeutics' Obesity Drug Market Outlook
- Clinical Trial Catalyst: Viking Therapeutics is set to release maintenance study data in Q3, which could provide crucial insights into the long-term use of its obesity drug VK2735, with positive results likely to enhance market competitiveness and attract more investor interest.
- Dual-Track Development Strategy: VK2735, a dual GLP-1/GIP receptor agonist, is advancing in both subcutaneous and oral formulations, and the growing market demand for such flexibility may allow Viking to stand out in competition against giants like Novo Nordisk and Eli Lilly.
- Sufficient Funding for Development: As of the end of Q1, Viking Therapeutics had a cash runway of $603 million, which is adequate to support all its R&D plans through 2027, ensuring ongoing investment and innovation in the obesity drug market.
- Optimistic Analyst Ratings: According to Koyfin, 18 out of 20 analysts covering VKTX rate it as 'Buy' or higher, with a 12-month average price target of $92.58, indicating a potential upside of about 166% from the last closing price, reflecting strong market confidence in its future performance.
See More
GLP-1 Drug Market Poised for Significant Growth
- Market Potential: Analysts at Grand View Research estimate that the global GLP-1 drug market will exceed $185 billion by 2033, with a compound annual growth rate of 12.4%, indicating significant growth potential that could transform the healthcare landscape.
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, generated $19.8 billion in revenue during Q1 2026, reflecting an impressive growth rate of 56%, showcasing the company's robust competitive position in the rapidly expanding GLP-1 market.
- Viking Therapeutics' Potential: Although Viking Therapeutics has no approved drugs yet, its GLP-1 drug VK2735 has shown promising results in clinical trials, and if approved, could significantly boost its market value and become an attractive acquisition target for larger healthcare firms.
- Investment Risks and Opportunities: While Eli Lilly's high valuation at a 39x P/E ratio may seem steep, its strong fundamentals make it a compelling long-term investment, whereas Viking Therapeutics presents a higher risk-reward profile, appealing to investors looking for diversification.
See More
Viking Therapeutics Faces Key Catalysts Ahead
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in phase 3 trials, with data expected next year; if it can replicate its strong phase 2 results, the stock could see significant appreciation, attracting more investor interest.
- Market Potential: With the anti-obesity drug market projected to grow rapidly over the next decade, Viking Therapeutics faces heightened market expectations, and despite an 8% decline in stock price this year, it is still viewed as a potential investment opportunity.
- Product Line Expansion: The company plans to initiate late-stage studies for an oral formulation of VK2735 by year-end, which could further strengthen its position in the competitive weight-loss drug market and enhance future revenue potential.
- Risks and Opportunities: While Viking Therapeutics' stock is seen as an attractive investment option, investors must be aware of potential risks, particularly setbacks in clinical trials, and it is advisable for risk-tolerant investors to consider initiating a small position.
See More
Anti-Obesity Drug Market Faces Potential Disruption
- Market Dominance: Eli Lilly and Novo Nordisk dominate the U.S. obesity and diabetes treatment market with their GLP-1 drugs, creating a potential duopoly that presents opportunities for new entrants to challenge the status quo.
- Viking Therapeutics' Competitiveness: Viking Therapeutics' VK2735 shows promising early data in phase 2 trials, with participants losing up to 14.7% of their weight over 13 weeks, indicating its competitive edge in a market with limited share.
- Market Potential: If the anti-obesity drug market reaches $100 billion in the next decade, Viking only needs to capture 1% of the market to significantly boost its valuation, highlighting its potential threat to the revenues of Lilly and Novo Nordisk.
- Clinical Trial Progress: VK2735's phase 3 trials have just completed enrollment, with results expected by 2027; if these results confirm earlier data, it will greatly enhance its competitive position in the obesity drug market.
See More
Viking Therapeutics Aims to Disrupt Obesity Drug Market
- Competitive Candidate: Viking Therapeutics' VK2735 demonstrated strong early data in two phase 2 trials, with participants losing 14.7% and 12.2% of their weight over 13 weeks, indicating its potential to compete with Eli Lilly and Novo Nordisk in the obesity drug market.
- Market Share Opportunity: With a market cap of just $3.5 billion, capturing even 1% of the projected $100 billion weight-loss drug market could significantly elevate Viking's valuation, providing substantial returns for shareholders.
- Clinical Trial Progress: The phase 3 trials for the injectable formulation of VK2735 completed enrollment earlier this year, with top-line data not expected until 2027, while the oral formulation's phase 3 trial is anticipated to begin by the end of this year.
- Industry Competitive Landscape: Although VK2735 shows competitive potential in the short term, it must prove its long-term efficacy against late-stage candidates like Eli Lilly's retatrutide and Novo Nordisk's CagriSema to secure a foothold in the market.
See More
